September 18, 2023
Alliance A092105: Randomized phase 2 study of nivolumab and ipilimumab with or without cabozantinib in patients with advanced nasopharyngeal carcinoma that have progressed after platinum treatment and immunotherapy
Overview: Alliance investigator Glenn J. Hanna, MD, of Dana-Farber Cancer Institute, leads this phase II trial that tests how well nivolumab and ipilimumab immunotherapy with or without cabozan
September 8, 2023
The phase III Alliance trial CALGB 90203 evaluated neoadjuvant chemohormonal therapy for high-risk localized prostate cancer before radical prostatectomy. In the Journal of the National Cancer Institute article, researchers share where they further dissected the molecular features of post-treated prostate cancer along with long-term clinical outcomes to explore mechanisms of response and resistance to che
Alliance A052101: A randomized phase 3 trial of continuous vs. intermittent maintenance therapy with zanubrutinib as upfront treatment in older patients with mantle cell lymphoma
Overview: Alliance investigator Anne Beaven, MD, of University of North Carolina Chapel Hill, leads this phase III trial that tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituxi
